World Journal of
Pharmaceutical and Life Sciences

NOACS: AN EMERGING CLASS OF ORAL ANTICOAGULANTS-A REVIEW ARTICLE

*Besty Elizabeth Babu, Dr. Sudeep Balakrishnan and Dr. Siraj Sundaran

ABSTRACT

NOACs commonly known as novel oral anticoagulants, which are non-vitamin K antagonist. Which are relatively newer in the market. It has displaced vitamin K antagonists, notably warfarin, for many indications. These agents are dabigatran, rivaroxaban, apixaban, and edoxaban. The drugs are licensed to prevent stroke and also systemic embolism in patients on treatment for atrial fibrillation and prevent venous thromboembolism. Rivaroxaban and apixaban are approved for prophylaxis of thrombus following surgical hip or knee arthroplasty. The recent surveys reveal that use of NOACs has steeply increased due to its safety profile and convenience to use. Also, the studies have shown that NOACs have lesser bleeding complications and associated mortality in contrast to traditional anticoagulants.

[Full Text Article]   [Download Certificate]